Phase 3 Study to Assess Resiniferatoxin vs Standard of Care for the Treatment of Intractable Cancer Pain

NCT04572776 | Withdrawn Phase 3 DMC FDA Drug

• 1 other identifier: STI-RTX-300x
• Study Type: interventional
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

This is a Phase 3 study to assess the safety and efficacy of a single epidural administration of Resiniferatoxin versus standard of care for the treatment of intractable pain associated with cancer.

Conditions

Pain, Intractable; Pain Cancer

Keywords

pain; cancer pain; intractable pain; RTX; resiniferatoxin

Outcome Measures

Primary Outcomes (1)

• Change in worst pain as assessed using the Numeric Pain Rating Scale (NPRS)

  Change from baseline to Week 4 in the intensity of worst pain over the previous 24 hours in the area targeted for treatment as measured by the 11-point NPRS (0-10 where 0 is no pain and 10 is worst pain imaginable)

  Baseline to Week 4

Secondary Outcomes (6)

• Change in worst pain as assessed using the NPRS

  Baseline to Weeks 8 and 12

• Change in area under the curve (AUC) of worst pain as assessed using the NPRS

  Baseline through Week 4

• Incidence and severity of adverse events (AEs)

  Baseline through Week 12

• Change in Quality of Life (QOL) as assessed using the modified Brief Pain Inventory-Short Form (BPI-SF)

  Baseline to Week 4

• Duration of response in subjects who experienced ≥20% decrease from baseline in worst pain as assessed using the NPRS

  Randomization through Week 12

Study Arms (2)

Resiniferatoxin

EXPERIMENTAL

Single dose of Resiniferatoxin (25 mcg in 3 mL) injected epidurally

Drug: Resiniferatoxin

Standard of Care

ACTIVE COMPARATOR

Standard of care treatment as determined by the investigator

Other: Standard of Care

Interventions

Resiniferatoxin DRUG

Resiniferatoxin is a TRPV-1 agonist which works by specifically ablating nociceptive nerve fibers.

Also known as: RTX

Resiniferatoxin

Standard of Care OTHER

Standard of care for intractable pain with the exception of intra-thecal pump placement as determined by the investigator.

Also known as: SOC

Standard of Care

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Histologically confirmed clinical diagnosis of advanced cancer or metastasis.
• Pain in the target area (lower thoracic or chest level down to lower extremities) most likely attributed to cancer as per Investigator.
• Pain severity at the target area is moderate-to-severe, defined as worst pain ≥6 on the NPRS during screening (average of the 3 days prior to Day 1), despite available pain therapy or analgesia. Subjects with multiple sites of pain are eligible as long as the intensity of pain at the intended target location for treatment fulfills the score of ≥6 and can be differentiated from other areas.
• Must report NPRS scores in the daily diary for at least 3 days prior to Day 1.
• Must be at least 18 years of age or older at Screening.
• Subject has reasonable expectation that they will be able to complete the study (through at least the week 4 visit).
• Life expectancy of at least 6 months at screening
• Minimum Karnofsky score of 50 at screening
• Sexually active female participants of childbearing potential must be willing to use an effective method of contraceptive method to avoid pregnancy
• Must have provided written informed consent which includes signing the institutional review board approved consent form prior to participating in any study related activity.
• Must be willing and capable of understanding and cooperating with the requirements of the study, including the ability to perform/undergo all required assessments for the duration of the study.
• Must be able to understand, and complete study related forms and adequately communicate with the investigator and/or site staff.

You may not qualify if:

• Undergoing or have plans to undergo changes to current cancer treatment from 7 days prior to Day 1 to 4 weeks after Day 1. Continuation of existing anti-cancer therapy without any planned change in dose or regimen is permitted. Participants may receive new cancer therapy 4 weeks after Day 1 including investigational agents in another clinical trial while participating in this study. If participating in another trial, it is requested that the subject agree to continue clinic visits and completion of patient diaries in this trial.
• Participants with leptomeningeal metastases in the lumbar area.
• Level of intended epidural injection is in the site of prior lumbar spine surgical procedures, such as posterior spinal fusions, that could impair the ability to perform the injection, as assessed by the Investigator.
• Evidence of increased intracranial pressure as determined by symptoms, history, physical examination, and/or magnetic resonance imaging (MRI).
• Patients with an intra-thecal pump implanted within 2 weeks of the baseline visit will be excluded. Pump placement during the study will not be permitted for 4 weeks after the study drug is administered; and existing pump medications cannot be changed during that same initial 4 week period.
• Has evidence of a non-correctable coagulopathy or hemostasis problem at Screening (V1) or Baseline (V2) as defined by:
• Prothrombin Time/International Normalized Ratio ≥1.3 times upper limit of normal (ULN) range with blood drawn within 1 week of the planned injection.
• Partial thromboplastin time ≥1.5times upper limit of normal (ULN) with blood drawn within 1 week of the planned injection.
• Platelet count \<75,000 cells/mm3 with blood drawn within 1 week of the planned injection. Participants must stop any anticoagulant (e.g., warfarin) or antiplatelet (e.g., aspirin) before and during IP administration according to acceptable medical guidelines. Participants with abnormal PT or PTT at Screening, but whose PT or PTT is expected to normalize once anticoagulation is held, are eligible as long as the PT or PTT has normalized prior to the planned injection.
• Participants with a total neutrophil count \<750 cells/mm3 at Screening (V1) or Baseline (V2).
• Is febrile or has other evidence of an infection within 24 hours of the planned injection.
• Has an allergy or hypersensitivity to capsaicin, or radiographic contrast agents used in diagnostic imaging studies.
• Female participants who are pregnant at Screening (V1) or Day 1 (V2), are planning on becoming pregnant, or are currently breastfeeding.
• Participants with any medical condition that, in the Investigator's opinion, could adversely impact study participation or safety, the conduct of the study, or interfere with the pain assessments.
• Participants with additional loci of pain above the midthoracic level or other pain disorder due to noncancer etiology at Screening (V1), unless both the investigator and the subject are clearly able to distinguish this pain from the target pain due to cancer.

Sponsors & Collaborators

• Sorrento Therapeutics, Inc.: lead

MeSH Terms

Conditions

Pain, Intractable; Cancer Pain; Pain

Interventions

resiniferatoxin; Standard of Care

Condition Hierarchy (Ancestors)

Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Quality Indicators, Health Care; Quality of Health Care; Health Services Administration; Health Care Quality, Access, and Evaluation

Study Officials

• Monica Luchi, MD

  Sorrento Therapeutics

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Masking Details: Follow-up visit examinations will be performed by a blinded outcomes assessor.
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 29, 2020
• First Posted: October 1, 2020
• Study Start: December 1, 2020
• Primary Completion: March 1, 2023
• Study Completion: March 1, 2023
• Last Updated: November 9, 2021

Record last verified: 2021-11